<DOC>
	<DOCNO>NCT00958880</DOCNO>
	<brief_summary>The purpose study investigate utility Yohimbine hydrochloride facilitate fear extinction sample patient social phobia treat CBT .</brief_summary>
	<brief_title>Yohimbine Enhance Cognitive Behavioral Therapy ( CBT ) Social Anxiety</brief_title>
	<detailed_description>The primary aim determine relative efficacy exposure-based CBT social phobia conduct adjunctive acute ( prior four five session ) administration either Yohimbine hydrochloride ( 10.8 mg ) placebo core exposure session . Based available evidence , investigator hypothesize acute treatment Yohimbine hydrochloride prior exposure-based CBT would facilitate extinction fear occur treatment would enhance treatment outcome .</detailed_description>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Yohimbine</mesh_term>
	<criteria>1 . Male female outpatient 18 65 year age primary psychiatric diagnosis ( designate patient important source current distress ) nongeneralized social anxiety disorder ( SAD ) Generalized Social Anxiety Disorder ( GSAD ) significant fear public speaking define DSMIV criterion . 2 . Severity social phobia least 3 CGI scale rat severity public speaking anxiety 3 . Willingness ability comply requirement study protocol . 1 . A lifetime history bipolar disorder , schizophrenia , psychosis , delusional disorder obsessivecompulsive disorder ; eat disorder past 6 month ; organic brain syndrome , mental retardation cognitive dysfunction could interfere capacity engage therapy ; history substance ( amphetamine , benzodiazepine , barbiturate , cocaine metabolite , marijuana , narcotic , sedative hypnotic ) abuse dependence alcohol abuse dependence ( nicotine ) last 6 month otherwise unable commit refrain alcohol use acute period study participation . 2 . Patients posttraumatic stress disorder within past 6 month exclude . Entry patient mood anxiety disorder permit social anxiety disorder judge predominant disorder , order increase accrual clinically relevant sample . Patients significant suicidal ideation ( BDI item 9 score &gt; 1 ) enact suicidal behavior within 6 month prior intake exclude study participation refer appropriate clinical intervention . 3 . Given Yohimbine hydrochloride frequently use adjunctive medication order decrease side effect commonly result antidepressant use ( Pollack &amp; Smoller , 1996 ) , antidepressant anxiolytic medication acceptable stabilize least 8 week prior baseline assessment . However , individual take monoamine oxidase inhibitor tricyclic antidepressant exclude study unless able willing discontinue medication prior baseline screen . 4 . Individuals take antihistamine strattera ( atomoxetine ) exclude study unless able willing discontinue medication prior baseline screen 5 . Evidence interview physical exam significant general medical condition ( e.g renal , endocrine , hepatic , respiratory , cardiovascular , hematologic , immunologic cerebrovascular disease , malignancy ) may interfere interpretation safety efficacy evaluation opinion prescribe physician . 6 . Resting blood pressure â‰¥ 160 systolic and/or 100 diastolic . Individuals currently treat high blood pressure meeting criterion eligible . 7 . Significant personality dysfunction likely interfere study participation . 8 . Patients current past history seizures 9 . Pregnant woman , lactate woman , woman childbearing potential use medically accept form contraception ( e.g. , IUD , oral contraceptive , barrier device , condom foam , implant progesterone rod stabilize least 3 month ) . A urine pregnancy test perform female subject childbearing potential screening visit . 10 . Any concurrent psychotherapy initiate within 3 month baseline , ongoing psychotherapy duration direct specifically toward treatment SAD exclude . Prohibited psychotherapy include CBT psychodynamic therapy focus explore specific , dynamic cause phobic symptomatology provide management skill . General supportive therapy initiate &gt; 3 month prior acceptable . 11 . Prior nonresponse adequatelydelivered exposure ( i.e. , define patient 's report receive specific regular exposure assignment part previous treatment ) exclude participant study . 12 . Patients history head trauma cause loss consciousness , seizure ongoing cognitive impairment . 13 . Patients unable understand study procedure participate inform consent process .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>